CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Bristol-Myers Squibb Co - BMY CFD

54.18
1.82%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Bristol-Myers Squibb Co ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 53.21
Open* 53.69
1-Year Change* -21.08%
Day's Range* 53.4 - 54.36
52 wk Range 48.25-75.18
Average Volume (10 days) 15.62M
Average Volume (3 months) 310.78M
Market Cap 101.92B
P/E Ratio 12.70
Shares Outstanding 2.03B
Revenue 44.94B
EPS 3.94
Dividend (Yield %) 4.79138
Beta 0.37
Next Earnings Date Feb 2, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 54.18 0.71 1.33% 53.47 54.42 53.34
Mar 27, 2024 53.21 0.09 0.17% 53.12 53.63 52.80
Mar 26, 2024 52.50 0.16 0.31% 52.34 52.59 51.98
Mar 25, 2024 52.20 0.25 0.48% 51.95 52.68 51.84
Mar 22, 2024 51.86 0.28 0.54% 51.58 52.39 51.46
Mar 21, 2024 51.54 -0.34 -0.66% 51.88 52.59 51.51
Mar 20, 2024 51.83 0.35 0.68% 51.48 52.10 51.19
Mar 19, 2024 51.75 0.02 0.04% 51.73 51.87 51.33
Mar 18, 2024 51.53 -0.93 -1.77% 52.46 52.64 51.48
Mar 15, 2024 52.38 0.48 0.92% 51.90 53.14 51.90
Mar 14, 2024 52.46 0.15 0.29% 52.31 52.62 51.75
Mar 13, 2024 52.58 -1.93 -3.54% 54.51 54.96 52.54
Mar 12, 2024 54.35 0.10 0.18% 54.25 54.54 53.77
Mar 11, 2024 54.33 0.43 0.80% 53.90 54.51 53.76
Mar 8, 2024 53.72 0.36 0.67% 53.36 54.20 53.29
Mar 7, 2024 53.22 -0.30 -0.56% 53.52 53.68 52.93
Mar 6, 2024 53.32 1.04 1.99% 52.28 53.75 52.28
Mar 5, 2024 51.76 0.79 1.55% 50.97 52.05 50.93
Mar 4, 2024 50.86 -0.44 -0.86% 51.30 52.14 50.66
Mar 1, 2024 50.83 -0.05 -0.10% 50.88 51.02 50.38

Bristol-Myers Squibb Co Events

Time (UTC) Country Event
Thursday, April 25, 2024

Time (UTC)

12:00

Country

US

Event

Q1 2024 Bristol-Myers Squibb Co Earnings Call
Q1 2024 Bristol-Myers Squibb Co Earnings Call

Forecast

-

Previous

-

Time (UTC)

12:30

Country

US

Event

Q1 2024 Bristol-Myers Squibb Co Earnings Release
Q1 2024 Bristol-Myers Squibb Co Earnings Release

Forecast

-

Previous

-
Wednesday, May 1, 2024

Time (UTC)

14:00

Country

US

Event

Bristol-Myers Squibb Co Annual Shareholders Meeting
Bristol-Myers Squibb Co Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 46159 46385 42518 26145 22561
Revenue 46159 46385 42518 26145 22561
Cost of Revenue, Total 10074 9601 11133 7804 6436
Gross Profit 36085 36784 31385 18341 16125
Total Operating Expense 36494 37770 49365 19758 16175
Selling/General/Admin. Expenses, Total 7808 7688 7733 4870 4550
Research & Development 9411 9532 9519 5845 5052
Depreciation / Amortization 9595 10023 9688 1206 41
Unusual Expense (Income) 1721 2659 12819 1393 1449
Other Operating Expenses, Total -2115 -1733 -1527 -1360 -1353
Operating Income 9665 8615 -6847 6387 6386
Interest Income (Expense), Net Non-Operating -1862 -550 -71 -69 -380
Other, Net -90 33 47 -1343 -38
Net Income Before Taxes 7713 8098 -6871 4975 5968
Net Income After Taxes 6345 7014 -8995 3460 5003
Minority Interest -18 -20 -20 -21 -27
Net Income Before Extra. Items 6327 6994 -9015 3439 4976
Net Income 6327 6994 -9015 3439 4920
Income Available to Common Excl. Extra. Items 6327 6994 -9015 3439 4976
Income Available to Common Incl. Extra. Items 6327 6994 -9015 3439 4920
Diluted Net Income 6327 6994 -9015 3439 4920
Diluted Weighted Average Shares 2146 2245 2258 1712 1637
Diluted EPS Excluding Extraordinary Items 2.94828 3.11537 -3.99247 2.00876 3.03971
Dividends per Share - Common Stock Primary Issue 2.16 1.96 1.8 1.64 1.6
Diluted Normalized EPS 3.12954 3.81069 -0.19982 2.58034 3.78174
Total Extraordinary Items 0 -56
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 10966 11226 11337 11406 11218
Revenue 10966 11226 11337 11406 11218
Cost of Revenue, Total 2490 2840 2565 2573 2353
Gross Profit 8476 8386 8772 8833 8865
Total Operating Expense 8639 9090 8238 9180 8745
Selling/General/Admin. Expenses, Total 1938 1914 1762 2266 1930
Research & Development 2149 2252 2301 2510 2360
Depreciation / Amortization 2256 2257 2256 2343 2418
Unusual Expense (Income) 388 385 -95 320 263
Other Operating Expenses, Total -582 -558 -551 -832 -579
Operating Income 2327 2136 3099 2226 2473
Interest Income (Expense), Net Non-Operating -173 -245 -341 42 -313
Other, Net -17 -32 12 -409 49
Net Income Before Taxes 2137 1859 2770 1859 2209
Net Income After Taxes 1934 2077 2267 2025 1608
Minority Interest -6 -4 -5 -3 -2
Net Income Before Extra. Items 1928 2073 2262 2022 1606
Net Income 1928 2073 2262 2022 1606
Income Available to Common Excl. Extra. Items 1928 2073 2262 2022 1606
Income Available to Common Incl. Extra. Items 1928 2073 2262 2022 1606
Diluted Net Income 1928 2073 2262 2022 1606
Diluted Weighted Average Shares 2064 2102 2113 2122 2148
Diluted EPS Excluding Extraordinary Items 0.93411 0.9862 1.07052 0.95287 0.74767
Dividends per Share - Common Stock Primary Issue 0.57 0.57 0.57 0.54 0.54
Diluted Normalized EPS 0.95736 1.02141 0.88689 0.01084 0.99488
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 27273 33262 30192 29354 17160
Cash and Short Term Investments 9253 16966 15831 15393 8884
Cash & Equivalents 9123 13979 14546 12346 6911
Short Term Investments 130 2987 1285 3047 1973
Total Receivables, Net 9886 9369 8501 7685 5747
Accounts Receivable - Trade, Net 8151 7979 7219 6476 4636
Total Inventory 2339 2095 2074 4293 1195
Prepaid Expenses 3547 2786 1799 754 218
Other Current Assets, Total 2248 2046 1987 1229 1116
Total Assets 96820 109314 118481 129944 34986
Property/Plant/Equipment, Total - Net 7475 6968 6745 6956 5027
Property/Plant/Equipment, Total - Gross 11639 11001 10330 10911 8845
Accumulated Depreciation, Total -4164 -4033 -3585 -3955 -3818
Goodwill, Net 21149 20502 20547 22488 6538
Intangibles, Net 35859 42527 53243 63969 1091
Long Term Investments 2187 2713 4509 4601 1775
Other Long Term Assets, Total 2877 3342 3245 2576 3395
Total Current Liabilities 21890 21868 19080 18304 10654
Accounts Payable 3040 2949 2713 2445 1892
Accrued Expenses 10374 10104 9582 8100 5687
Notes Payable/Short Term Debt 367 184 340 583 454
Current Port. of LT Debt/Capital Leases 3897 4764 2000 2763 1249
Other Current Liabilities, Total 4212 3867 4445 4413 1372
Total Liabilities 65759 73368 80659 78346 20955
Total Long Term Debt 35056 39605 48336 43387 5646
Long Term Debt 35056 39605 48336 43387 5646
Minority Interest 57 60 60 100 96
Other Liabilities, Total 6590 7334 7776 10101 4559
Total Equity 31061 35946 37822 51598 14031
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 292 292 292 292 221
Additional Paid-In Capital 45165 44361 44325 43709 2081
Retained Earnings (Accumulated Deficit) 25503 23820 21281 34474 34065
Treasury Stock - Common -38618 -31259 -26237 -25357 -19574
Unrealized Gain (Loss) 0 2 11 6 -30
Other Equity, Total -1281 -1270 -1850 -1526 -2732
Total Liabilities & Shareholders’ Equity 96820 109314 118481 129944 34986
Total Common Shares Outstanding 2075 2153 2221 2228 1624
Total Preferred Shares Outstanding
Deferred Income Tax 2166 4501 5407 6454
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 27632 28074 27086 27273 26796
Cash and Short Term Investments 7685 8730 9269 9253 9027
Cash & Equivalents 7514 8372 8995 9123 7734
Short Term Investments 171 358 274 130 1293
Total Receivables, Net 15647 15059 13405 9886 13240
Accounts Receivable - Trade, Net 8817 8530 8359 8151 8467
Total Inventory 2436 2364 2605 2339 2074
Other Current Assets, Total 1864 1921 1807 2248 2455
Total Assets 91263 93489 94281 96820 98196
Property/Plant/Equipment, Total - Net 7848 7629 7605 7475 6918
Property/Plant/Equipment, Total - Gross 12499 12106 11847 11639 11057
Accumulated Depreciation, Total -4651 -4477 -4242 -4164 -4139
Goodwill, Net 21147 21163 21162 21149 21112
Intangibles, Net 28950 31303 33569 35859 38179
Long Term Investments 1882 1991 2005 2187 1959
Other Long Term Assets, Total 3804 3329 2854 2877 3232
Total Current Liabilities 23462 20150 19085 21890 18930
Accounts Payable 2813 3069 3194 3040 2595
Accrued Expenses 10913 9311 8589 10374 10006
Notes Payable/Short Term Debt 594 606 498 367 229
Current Port. of LT Debt/Capital Leases 4873 2414 2254 3897 1903
Other Current Liabilities, Total 4269 4750 4550 4212 4197
Total Liabilities 62265 61516 62457 65759 65525
Total Long Term Debt 32137 34656 35078 35056 36966
Long Term Debt 32137 34656 35078 35056 36966
Deferred Income Tax 399 751 1568 2166 2881
Minority Interest 64 57 62 57 63
Other Liabilities, Total 6203 5902 6664 6590 6685
Total Equity 28998 31973 31824 31061 32671
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 292 292 292 292 292
Additional Paid-In Capital 44849 45299 45140 45165 44956
Retained Earnings (Accumulated Deficit) 28218 27449 26568 25503 24675
Treasury Stock - Common -43075 -39680 -38808 -38618 -36411
Unrealized Gain (Loss) -2 0 0
Other Equity, Total -1284 -1387 -1368 -1281 -841
Total Liabilities & Shareholders’ Equity 91263 93489 94281 96820 98196
Total Common Shares Outstanding 2034 2089 2100 2075 2124
Prepaid Expenses 3547
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 6345 7014 -8995 3460 4947
Cash From Operating Activities 13066 16207 14052 8067 5940
Cash From Operating Activities 10276 10686 10380 1746 637
Deferred Taxes -2738 -1393 983 -924 86
Non-Cash Items 1412 1153 10701 720 94
Cash Taxes Paid 5400 3500 3400 1503 747
Cash Interest Paid 1400 1500 1600 414 212
Changes in Working Capital -2229 -1253 983 3065 176
Cash From Investing Activities -1062 -538 -10859 -9770 -874
Capital Expenditures -1118 -973 -753 -836 -951
Other Investing Cash Flow Items, Total 56 435 -10106 -8934 77
Cash From Financing Activities -16962 -16224 -1151 7621 -3535
Financing Cash Flow Items 984 641 542 -53 -54
Total Cash Dividends Paid -4634 -4396 -4075 -2679 -2613
Issuance (Retirement) of Stock, Net -8001 -6287 -1546 -7300 -320
Issuance (Retirement) of Debt, Net -5311 -6182 3928 17653 -548
Foreign Exchange Effects -33 -102 111 -9 -41
Net Change in Cash -4991 -657 2153 5909 1490
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 2267 6345 4320 2712 1283
Cash From Operating Activities 2970 13066 9760 6073 3812
Cash From Operating Activities 2429 10276 7755 5167 2584
Deferred Taxes -548 -2738 -2114 -1469 -687
Non-Cash Items 182 1412 1570 1598 994
Changes in Working Capital -1360 -2229 -1771 -1935 -362
Cash From Investing Activities -210 -1062 -2275 -194 95
Capital Expenditures -278 -1118 -772 -525 -253
Other Investing Cash Flow Items, Total 68 56 -1503 331 348
Cash From Financing Activities -3050 -16962 -13716 -9173 -5653
Financing Cash Flow Items -92 984 805 752 333
Total Cash Dividends Paid -1196 -4634 -3489 -2335 -1185
Issuance (Retirement) of Stock, Net -250 -8001 -5585 -5000 -5000
Issuance (Retirement) of Debt, Net -1512 -5311 -5447 -2590 199
Foreign Exchange Effects 13 -33 -128 -62 9
Net Change in Cash -277 -4991 -6359 -3356 -1737

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Bristol-Myers Squibb Company profile

What is Bristol-Myers Squibb Co.?

The Bristol-Myers Squibb Company is an international biopharmaceutical company specialising in discovering, developing and delivering innovative biopharmaceutical products and medicines to patients who suffer from serious diseases. Bristol-Myers Squibb provides medicines to help people fight cancer, hepatitis B and C, cardiovascular disease, HIV and AIDS. The company supplies its products to retail and wholesale pharmacies, governmental entities, and hospitals throughout the world.
 

What’s the history behind the company?

1858 – The Squibb corporation is founded by Edward Robinson Squibb in New York.
 
1887 – The Clinton Pharmaceutical company i purchased by William McLaren Bristol and John Ripley Myers. Two years later they rename it as “Bristol, Myers and Company”, and later, following Myers death in 1899 as the “Bristol-Myers Corporation”.
 
1903 – Sal Hepatica, a laxative salt is developed and released marking the first product for the company.
 
1943 – Acquisition of Cheplin Biological Laboratories, Bristol laboratories in 1945 creating antibiotics, is met with competition from Squibbs.
 
1989 – Bristol-Myers merges with Squibb to form Bristol-Myers Squibb, creating one of the world’s largest pharmaceutical companies.
 
1998 – Development of Excedrin Migraine, one of the first migraine medications available without a prescription in the US.
 
2004 – Bristol-Myers Squibb pays $150 million in a settlement for accounting fraud, the company does not admit or deny guilt. In 2006, the company is hit again by charges and pays $2.1 million to the Federal Trade Commission.
 
2008 – The company undertakes a number of partnerships, including therapy for cardiovascular diseases with KAI pharmaceuticals, cancer therapies with Kosan, and two novel therapies for cancer with Exelixis. These collaborations continue into 2009 with more added.
 
2010 – Lamberto Andreotti took over as CEO of Bristol-Myers Squibb. By 2012, the company’s net sales reach $17.6 billion.
 
2015 – Dr. Giovanni Caforio becomes the head of the company.
 

About the company

Bristol-Myers Squibb operates worldwide with locations such as Asia, including China and Japan, Southeast Asia in Bangalore India, across Europe in Belgium, England, France, Ireland and Italy, and North America. This includes a number of research and development facilities, vital to the creation of new pharmaceutical products.
 
Across its facilities, the company employs approximately 23,700 people. To date, Dr. Giovanni Caforio is the Chairman and CEO of the company with Charles Bancroft as CFO.
 
The company has numerous awards and achievements, including 2018 Best-of-the-Best Corporations for Inclusion by National Business Inclusion Consortium, Fortune’s World’s Most Admired Companies, Dow Jones' 2017 North American Index of Leading Sustainable Companies, and Forbes America’s Best Employers for 2016.
 

Key Statistics

  • Revenue in 2017 – $20.78 billion
  • Net income in 2017 – $975 million
  • Total assets in 2017 – 33.55 billion
  • Total equity in 2017 – 11.85 billion

Major acquisitions

  • Adnexus Therapeutics – 2007
  • Kosan Biosciences – 2008
  • Medarex – 2009
  • ZymoGenetics – 2010
  • Amira Pharmaceuticals – 2011
  • Inhibitex Inc. – 2012
  • Amylin Pharmaceuticals and AstraZeneca – 2018
  • iPierian – 2014
  • Flexus Biosciences – 2015
  • Cardioxyl – 2015
  • Padlock Therapeutics – 2016
  • Cormorant Pharmaceuticals – 2016
  • IFM Therapeutics – 2017

Where is Bristol-Myers Squibb Co. traded?

Bristol-Myers Squibb is traded on the New York Stock Exchange (NYSE) under the ticker BMY. It is also a component of the S&P 100 and S&P 500. Trade the latest Bristol-Myers Squibb share price with Capital.com, explore the most up-to-date BMY charts, and delve into this pharmaceutical company.
Industry: Pharmaceuticals (NEC)

Route 206 And Province Line Road
PRINCETON
NEW JERSEY 08543
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.62 Price
-1.590% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

70,126.15 Price
-0.570% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading